Radioembolisation with chemotherapy for colorectal liver metastases

Challenges in first line ALK+ NSCLC and emerging data on ALK TKIs

IMpower010: A Phase 3 study of atezolizumab vs best supportive care after adjuvant chemotherapy in stage IB-IIIA NSCLC

ESMO 2021 Roundup

Managing patients with EGFR exon 20 ins in NSCLC and EGFR TKI toxicity

Abiraterone acetate plus prednisolone added to ADT + docetaxel, gives 25% reduction in risk of death compared to ADT + docetaxel alone in prostate cancer

FOLFOXIRI + bevacizumab + atezolizumab versus FOLFOXIRI + bevacizumab as first-line treatment of unresectable mCRC patients

Impact of biomarkers on pCR and survival after T-DM1 with or without ET vs trastuzumab and ET in HER2/HR positive early BC

Phase II trial: Tamoxifen + taselisib or placebo in patients with hormone receptor positive (HR+)/HER2- metastatic breast cancer

MRD-guided therapy debate

Cabozantinib in combination with atezolizumab in patients with mCRPC

ESMO President: What to watch for at ESMO 2021